Archive: September 08 2020

Find relevant news articles from other European projects, below:

CARAMBA  EURE-CART  CARAT Network ATECT PROCROP T2EVOLVE

Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:


blood a

Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large...

Cancer-associated venous thromboembolism (VTE) constitutes a major cause of morbidity and mortality in patients with hematologic malignancies.1 VTE can occur after chimeric antigen receptor (CAR) T-cell therapy, whereas coagulopathy in the form of low fibrinogen and bleeding can be complications of cytokine release syndrome (CRS).

Visit website
blood a1

Enhancing antitumor immunity through checkpoint blockade as a therapeutic strate...

  Sep 08 2020 Tagged ICI, NHL, TCL, PD-1, PD-L1

The majority of historical therapies for managing T-cell lymphomas (TCLs) have consisted of T-cell–depleting strategies. Unfortunately, these forms of therapies can hamper the ability to mount effective antitumor immune responses. Recently, the use of checkpoint inhibitors has revolutionized the therapy of solid and hematologic malignancies.

Visit website